SG11201407649RA - Method for treating non-small cell lung cancer - Google Patents
Method for treating non-small cell lung cancerInfo
- Publication number
- SG11201407649RA SG11201407649RA SG11201407649RA SG11201407649RA SG11201407649RA SG 11201407649R A SG11201407649R A SG 11201407649RA SG 11201407649R A SG11201407649R A SG 11201407649RA SG 11201407649R A SG11201407649R A SG 11201407649RA SG 11201407649R A SG11201407649R A SG 11201407649RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- lung cancer
- small cell
- cell lung
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261649092P | 2012-05-18 | 2012-05-18 | |
| PCT/US2013/041652 WO2013173757A1 (en) | 2012-05-18 | 2013-05-17 | Method for treating non-small cell lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407649RA true SG11201407649RA (en) | 2014-12-30 |
Family
ID=49581824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407649RA SG11201407649RA (en) | 2012-05-18 | 2013-05-17 | Method for treating non-small cell lung cancer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20130310440A1 (ja) |
| EP (1) | EP2849761A1 (ja) |
| JP (1) | JP2015522542A (ja) |
| KR (1) | KR20150024843A (ja) |
| CN (1) | CN104684564A (ja) |
| AR (1) | AR091090A1 (ja) |
| AU (1) | AU2013262589A1 (ja) |
| BR (1) | BR112014028787A2 (ja) |
| CA (1) | CA2874092A1 (ja) |
| EA (1) | EA201492148A1 (ja) |
| IL (1) | IL235459A0 (ja) |
| IN (1) | IN2014DN10390A (ja) |
| PH (1) | PH12014502569A1 (ja) |
| SG (1) | SG11201407649RA (ja) |
| TW (1) | TW201402132A (ja) |
| UY (1) | UY34812A (ja) |
| WO (1) | WO2013173757A1 (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2850318A1 (en) | 1999-02-26 | 2000-08-31 | The University Of British Columbia | Trpm-2 antisense therapy |
| US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| EP2569618B1 (en) | 2010-05-08 | 2017-03-01 | The Regents of the University of California | Sem scanner sensing apparatus, system and methodology for early detection of ulcers |
| CA2830195A1 (en) | 2011-03-15 | 2012-09-20 | Martin E. Gleave | Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer |
| CN104473973B (zh) * | 2014-12-19 | 2015-08-05 | 山东创新药物研发有限公司 | 一株戈氏梭菌驯化株的应用 |
| WO2016172263A1 (en) | 2015-04-24 | 2016-10-27 | Bruin Biometrics Llc | Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements |
| EP4295761A3 (en) | 2017-02-03 | 2024-05-08 | BBI Medical Innovations, LLC | Measurement of tissue viability |
| MX2019004926A (es) | 2017-02-03 | 2019-06-20 | Bruin Biometrics Llc | Medicion del edema. |
| AU2018217190B2 (en) | 2017-02-03 | 2020-04-30 | Bbi Medical Innovations, Llc | Measurement of susceptibility to diabetic foot ulcers |
| GB2584808B (en) | 2017-11-16 | 2021-07-28 | Bruin Biometrics Llc | Strategic treatment of pressure ulcer using sub-epidermal moisture values |
| US20190211044A1 (en) * | 2018-01-05 | 2019-07-11 | LifeUnit Inc. | Adjuvant Chemicals that Prevent Drug Tolerance and Persister Formation by Bacteria |
| GB2584226B (en) | 2018-02-09 | 2022-06-22 | Bruin Biometrics Llc | Detection of tissue damage |
| LT3861601T (lt) | 2018-10-11 | 2024-03-12 | Bruin Biometrics, Llc | Prietaisas su vienkartiniu elementu |
| WO2022169850A1 (en) | 2021-02-03 | 2022-08-11 | Bruin Biometrics, Llc | Methods of treating deep and early-stage pressure induced tissue damage |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900187B2 (en) * | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| US20060024692A1 (en) * | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| WO2005094899A1 (en) * | 2004-04-02 | 2005-10-13 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| EP2300825A4 (en) * | 2008-06-18 | 2012-04-25 | Abbott Lab | P / GF 1 COMPARATIVE DIAGNOSTIC PROCEDURES AND PRODUCTS |
| CN103958681A (zh) * | 2011-05-19 | 2014-07-30 | 泰华制药工业有限公司 | 治疗非小细胞肺癌的方法 |
-
2013
- 2013-05-16 UY UY0001034812A patent/UY34812A/es not_active Application Discontinuation
- 2013-05-17 IN IN10390DEN2014 patent/IN2014DN10390A/en unknown
- 2013-05-17 BR BR112014028787A patent/BR112014028787A2/pt not_active IP Right Cessation
- 2013-05-17 AU AU2013262589A patent/AU2013262589A1/en not_active Abandoned
- 2013-05-17 EP EP13791341.4A patent/EP2849761A1/en not_active Withdrawn
- 2013-05-17 JP JP2015512895A patent/JP2015522542A/ja active Pending
- 2013-05-17 CN CN201380030309.9A patent/CN104684564A/zh active Pending
- 2013-05-17 EA EA201492148A patent/EA201492148A1/ru unknown
- 2013-05-17 US US13/896,737 patent/US20130310440A1/en not_active Abandoned
- 2013-05-17 WO PCT/US2013/041652 patent/WO2013173757A1/en active Application Filing
- 2013-05-17 TW TW102117597A patent/TW201402132A/zh unknown
- 2013-05-17 KR KR20147035652A patent/KR20150024843A/ko not_active Application Discontinuation
- 2013-05-17 SG SG11201407649RA patent/SG11201407649RA/en unknown
- 2013-05-17 CA CA2874092A patent/CA2874092A1/en not_active Abandoned
- 2013-05-17 AR ARP130101729A patent/AR091090A1/es unknown
-
2014
- 2014-11-02 IL IL235459A patent/IL235459A0/en unknown
- 2014-11-18 PH PH12014502569A patent/PH12014502569A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014028787A2 (pt) | 2017-06-27 |
| EP2849761A1 (en) | 2015-03-25 |
| IL235459A0 (en) | 2014-12-31 |
| AU2013262589A1 (en) | 2015-01-22 |
| US20130310440A1 (en) | 2013-11-21 |
| CA2874092A1 (en) | 2013-11-21 |
| UY34812A (es) | 2013-12-31 |
| EA201492148A1 (ru) | 2015-04-30 |
| WO2013173757A8 (en) | 2015-04-30 |
| PH12014502569A1 (en) | 2015-01-21 |
| AR091090A1 (es) | 2014-12-30 |
| CN104684564A (zh) | 2015-06-03 |
| JP2015522542A (ja) | 2015-08-06 |
| IN2014DN10390A (ja) | 2015-08-14 |
| WO2013173757A1 (en) | 2013-11-21 |
| TW201402132A (zh) | 2014-01-16 |
| KR20150024843A (ko) | 2015-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407649RA (en) | Method for treating non-small cell lung cancer | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201907846VA (en) | Therapeutic rna | |
| SG11201908547VA (en) | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods | |
| SG11201408174UA (en) | Antibody formulation | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201806340YA (en) | Zika virus vaccine | |
| SG11201808693WA (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| SG11201408261UA (en) | Syringe | |
| SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407537YA (en) | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201408810TA (en) | Methods of treating arthritis | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201408460UA (en) | Inhibitors of the mir-15 family of micro-rnas | |
| SG11201407512VA (en) | High-concentration monoclonal antibody formulations | |
| SG11201407860PA (en) | Exendin-4 peptide analogues | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201406973PA (en) | Complement pathway modulators and uses thereof | |
| SG11201805184TA (en) | Combination therapy |